{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T13:21:48Z","timestamp":1781529708084,"version":"3.54.1"},"update-to":[{"DOI":"10.1002\/14651858.cd004554","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2004,10,18]],"date-time":"2004-10-18T00:00:00Z","timestamp":1098057600000}}],"reference-count":61,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004554.pub2","type":"journal-article","created":{"date-parts":[[2004,10,14]],"date-time":"2004-10-14T10:08:51Z","timestamp":1097748531000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease"],"prefix":"10.1002","volume":"2010","author":[{"given":"Katherine","family":"Deane","sequence":"first","affiliation":[{"name":"Newcastle University; Institute of Health & Society; 21 Claremont Place Newcastle-upon-Tyne UK NE2 4AA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sybille","family":"Spieker","sequence":"additional","affiliation":[{"name":"Marburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl E","family":"Clarke","sequence":"additional","affiliation":[{"name":"City Hospital, Sandwell and West Birmingham Hospitals NHS Trust; Department of Neurology; Dudley Road Birmingham West Midlands UK B18 7QH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,10,18]]},"reference":[{"key":"10.1002\/14651858.CD004554.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/archneur.55.8.1089","volume":"55","author":"Adler","year":"1998","journal-title":"Archives of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD004554.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/jnnp.63.4.421","article-title":"Catechol-O-methytransferase inhibition with tolcapone reduces the 'wearing-off' phenomenon and levodopa requirements in fluctuating Parkinsonian patients","volume":"63","author":"Baas","year":"1997","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD004554.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/jnnp.74.8.1071","article-title":"Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease. A randomized, placebo-controlled, double-blind six-month study","volume":"74","author":"Brooks","year":"2003","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"Supplement 3","key":"10.1002\/14651858.CD004554.pub2-BIB0004|cit4","first-page":"135","article-title":"The UK-Irish double-blind study of entacapone in Parkinson's disease","volume":"15","author":"Sagar","year":"2000","journal-title":"Movement Disorders"},{"issue":"3","key":"10.1002\/14651858.CD004554.pub2-BIB0005|cit5","first-page":"17","article-title":"Efficacy and safety of entacapone in non-fluctuating and fluctuating Parkinsonian patients. The UK-Irish long-term multicentre Study","volume":"7","author":"Sagar","year":"2000","journal-title":"European Journal of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD004554.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/mds.870120615","article-title":"Tolcapone added to levodopa in stable Parkinsoian patients: A double-blind placebo-controlled study","volume":"12","author":"Dupont","year":"1997","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004554.pub2-BIB0007|cit7","article-title":"Entacapone provides additional symptomatic benefits in Parkinson's disease (PD) patients treated with L_DOPA and a dopamine agonist who are experiencing wearing-off motor fluctuations: Results of a randomized, double-blind study","author":"Fenelon","year":"2002","journal-title":"AAN conf???"},{"issue":"5","key":"10.1002\/14651858.CD004554.pub2-BIB0008|cit8","first-page":"S40","article-title":"A multicentre, double-blind, placebo-controlled study to assess efficacy and safety of entacapone in Korean patients with Parkinson's disease experiencing end-of-dose deterioration","volume":"17","author":"Im","year":"2002","journal-title":"Movement Disorders"},{"issue":"1","key":"10.1002\/14651858.CD004554.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1212\/WNL.48.1.81","article-title":"Tolcapone improves motor fluctuation and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: A multicenter, double-blind, randomized, placebo-controlled trial","volume":"48","author":"Kurth","year":"1997","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD004554.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/1531-8257(200005)15:3<497::AID-MDS1012>3.0.CO;2-4","article-title":"Illness impact and adjustment to Parkinson's disease: before and after treatment with Tolcapone","volume":"15","author":"Welsh","year":"2000","journal-title":"Movement Disorders"},{"issue":"Supplement 2","key":"10.1002\/14651858.CD004554.pub2-BIB0011|cit11","first-page":"294","article-title":"Long-term safety of entacapone as an adjunct to levodopa in non-fluctuating and fluctuating patients with Parkinson's disease","volume":"13","author":"Myllyla VV and the Filomen Study Group","year":"1998","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004554.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1468-1331.2001.00168.x","article-title":"Twelve-month saftey of entacapone patients with Parkinson's disease","volume":"8","author":"Myllyla","year":"2001","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD004554.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1468-1331.1997.tb00358.x","article-title":"Efficacy and safety of tolcapone in levodopa-treated Parkinson's disease patients with 'wearing-off' phenomenon: a multicentre, double-blind, randomized, placebo-controlled trial","volume":"4","author":"Myllyla","year":"1997","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD004554.pub2-BIB0014|cit14","first-page":"S75","article-title":"Efficacy and safety of entacapone as an adjunct to levodopa treatment in Parkinson's disease (PD): Experience from the Austrain-German six-moths study","volume":"5","author":"Deuschl","year":"1999","journal-title":"Parkinsonism and Related Disorders"},{"key":"10.1002\/14651858.CD004554.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1034\/j.1600-0404.2002.1o174.x","article-title":"Efficacy and saftey of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-moth randomized placebo-controlled double-blind study in Germany and Austria (Celomen study)","volume":"105","author":"Poewe","year":"2002","journal-title":"Acta Neurologica Scandinavica"},{"issue":"Supplement 4","key":"10.1002\/14651858.CD004554.pub2-BIB0016|cit16","first-page":"S42","article-title":"Benefits of COMT inhibitors in levodop-treated parkinsonian patients. Results of clinical trials","volume":"55","author":"Kieburtz","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004554.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.410440228","article-title":"Reply (to Entacapone and Motor Fluctuations in Parkinson's disease, Riggs 1998)","author":"McDermott","year":"1998","journal-title":"Annals of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD004554.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ana.410420511","article-title":"Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients","volume":"42","author":"Parkinson's Study Group","year":"1997","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD004554.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.410440227","article-title":"Entacapone and Motor Fluctuations in Parkinson's Disease (Letter)","author":"Riggs","year":"1998","journal-title":"Annals of Neurology"},{"issue":"Supplement 3","key":"10.1002\/14651858.CD004554.pub2-BIB0020|cit20","first-page":"125","article-title":"Effect of entacapone on factors related to quality of life in Parkinson's disease","volume":"15","author":"The Nomecomt Study Group","year":"2000","journal-title":"Movement Disorders"},{"issue":"4","key":"10.1002\/14651858.CD004554.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/WNL.49.4.1066","article-title":"Tolcapone improves motor function in Parkinsonian patients with 'wearing-off' phenomenon: a double-blind, placebo-controlled, multicentre trial","volume":"49","author":"Rajput","year":"1997","journal-title":"Neurology"},{"issue":"Supplement 4","key":"10.1002\/14651858.CD004554.pub2-BIB0022|cit22","first-page":"S42","article-title":"Benefits of COMT inhibitors in levodopa-treated parkinsonian patients. Results of clinical trials","volume":"55","author":"Kieburtz","year":"2000","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD004554.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1212\/WNL.51.5.1309","article-title":"Entacapone enhances the response to levodopa in Parkinsonian patients with motor fluctuations","volume":"51","author":"Rinne","year":"1998","journal-title":"Neurology"},{"issue":"Supplement 3","key":"10.1002\/14651858.CD004554.pub2-BIB0024|cit24","first-page":"125","article-title":"Effect of entacapone on factors related to quality of life in Parkinson's disease","volume":"15","author":"The Nomecomt Study Group","year":"2000","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004554.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jnnp.60.1.36","article-title":"Entacapone prolongs levodopa response in a one month double blind study in Parkinsonian patients with levodopa related fluctuations","volume":"60","author":"Ruottinen","year":"1996","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD004554.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/syn.10034","article-title":"18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease","volume":"43","author":"Ceravolo","year":"2002","journal-title":"Synapse"},{"issue":"4","key":"10.1002\/14651858.CD004554.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00002826-199508000-00005","article-title":"Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegeline","volume":"18","author":"Davis","year":"1995","journal-title":"Clinical Neuropharmacology"},{"issue":"3","key":"10.1002\/14651858.CD004554.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/mds.870100321","article-title":"Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine\/carbidopa and selegeline","volume":"10","author":"Davis","year":"1995","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004554.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-2125.1995.tb05781.x","article-title":"Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa","volume":"40","author":"Dingemanse","year":"1995","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD004554.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000052104","article-title":"Efficacy and tolerability of entacapone as adjuvant therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: An open multicentre study","volume":"45","author":"Durif","year":"2001","journal-title":"European Neurology"},{"issue":"8-9","key":"10.1002\/14651858.CD004554.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/BF01285556","article-title":"Cognitive inprovement during Tolcapone treatment in PArkinson's disease","volume":"104","author":"Gasparini","year":"1997","journal-title":"Journal of Neural Transmission - General Section"},{"issue":"4","key":"10.1002\/14651858.CD004554.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1159\/000008052","article-title":"COMT inhibition by tolcapone further improves levodopa pharmacokinetics when combined with a dual-release formulation of levodopa\/benserazide. A novel principle in the treatment of Parkinson's disease","volume":"41","author":"Gasser","year":"1999","journal-title":"European Neurology"},{"issue":"4","key":"10.1002\/14651858.CD004554.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/mds.870130406","article-title":"A pilot evaluation of the tolerability, safety, and efficacy of Tolcapone alone and in combination with oral Selegeline in untreated Parkinson's disease patients","volume":"13","author":"Hauser","year":"1998","journal-title":"Movement Disorders"},{"issue":"5","key":"10.1002\/14651858.CD004554.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s002280050490","article-title":"Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy","volume":"54","author":"Jorga","year":"1998","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD004554.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1212\/WNL.44.1.77","article-title":"Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in Parkinsonian patients","volume":"44","author":"Kaakkola","year":"1994","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004554.pub2-BIB0036|cit36","unstructured":"Larsen JP Siden A Worm-Petersen J Gordin A Reinikainen K Kultalahti E-R Long-term efficacy and safety of entacapone in Parkinsonian patients with motor fluctuations: a Nordic open study of 3 years duration Proceedings of the XIV International Congress on Parkinson's Disease Helsinki, Finland 2001"},{"key":"10.1002\/14651858.CD004554.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1212\/WNL.58.4.564","article-title":"COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease","volume":"58","author":"Lee","year":"2002","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004554.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/0140-6736(93)90750-B","article-title":"Ro 40-7592, a COMT inhibitor, plus levodopa in Parkinson's disease","volume":"341","author":"Limousin","year":"1993","journal-title":"The Lancet"},{"issue":"3","key":"10.1002\/14651858.CD004554.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00002826-199506000-00006","article-title":"Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson's disease","volume":"18","author":"Limousin","year":"1995","journal-title":"Clinical Neuropharmacology"},{"issue":"4","key":"10.1002\/14651858.CD004554.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/mds.870120404","article-title":"Simultaneous MAO-B and COMT-Inhibition in L-Dopa-treated patients with Parkinson's disease","volume":"12","author":"Lyytinen","year":"1997","journal-title":"Movement Disorders"},{"issue":"1","key":"10.1002\/14651858.CD004554.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/00002826-200101000-00009","article-title":"The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-Dopa-treated patients with Parkinson's disease","volume":"24","author":"Lyytinen","year":"2001","journal-title":"Clinical Neuropharmacology"},{"issue":"2","key":"10.1002\/14651858.CD004554.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/jnnp.57.2.186","article-title":"Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease","volume":"57","author":"Merello","year":"1994","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1002\/14651858.CD004554.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1212\/WNL.44.5.913","article-title":"Effect of peripheral catechol-O-methytransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in Parkinsonian patients","volume":"44","author":"Nutt","year":"1994","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004554.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/jnnp.68.5.589","article-title":"The catechol-o-methyltransferase (COMT) inhibitor entacapone enhances that pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease","volume":"68","author":"Piccini","year":"2000","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD004554.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1212\/WNL.43.12.2685","article-title":"Catechol-O-methytransferase inhibitor tolcapone prolongs levodopa\/carbidopa action in parkinsonian patients","volume":"43","author":"Roberts","year":"1993","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD004554.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00002826-199619030-00004","article-title":"Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced Parkinsonian patients","volume":"19","author":"Ruottinen","year":"1996","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD004554.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1212\/WNL.44.7.1292","article-title":"The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: Implications for levodopa therapy of Parkinson's disease","volume":"44","author":"Sawle","year":"1994","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD004554.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/00002826-200107000-00004","article-title":"Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD","volume":"24","author":"Suchowersky","year":"2001","journal-title":"Clinical Neuropharmacology"},{"issue":"1","key":"10.1002\/14651858.CD004554.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0009-9236(98)90028-5","article-title":"Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease recieving entacapone","volume":"64","author":"Troconiz","year":"1998","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD004554.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.49.3.665","article-title":"Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment","volume":"49","author":"Waters","year":"1997","journal-title":"Neurology"},{"issue":"2-3","key":"10.1002\/14651858.CD004554.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF01273183","article-title":"Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symtoms and pharmacokinetics of levodopa patients with Parkinson's disease","volume":"104","author":"Yamamoto","year":"1997","journal-title":"Journal of Neural Transmissions - General Section"},{"key":"10.1002\/14651858.CD004554.pub2-BIB0052|cit52","first-page":"406","article-title":"A randomised placebo-controlled double-blind parallel group trial of entacapone in patients with fluctuating Parkinson's disease","volume":"36","author":"Zhang","year":"2003","journal-title":"Chinese Journal of Neurology"},{"key":"10.1002\/14651858.CD004554.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(05)61511-5","article-title":"Tolcapone and fulminant hepatitis","volume":"352","author":"Assal","year":"1998","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD004554.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0163-7258(98)00032-1","article-title":"New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease","volume":"81","author":"Bonifati","year":"1999","journal-title":"Pharmacological therapies"},{"issue":"10","key":"10.1002\/14651858.CD004554.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1007\/s004150050477","article-title":"The rise and fall of tolcapone","volume":"246","author":"Colosimo","year":"1999","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD004554.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(00)04337-3","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials","volume":"357","author":"Moher","year":"2001","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004554.pub2-BIB0057|cit57","unstructured":"The European Agency for the Evaluation of Medicines CPMP\/2457\/98: Recommendation for the suspension of the marketing authorisation for Tasmar (Tolcapone) Press release (London) EU\/1\/97\/044\/001 006"},{"issue":"6","key":"10.1002\/14651858.CD004554.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/mds.10342","article-title":"Entacapone-induced hepatotoxicity and hepatic dysfunction","volume":"17","author":"Fisher","year":"2002","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004554.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","article-title":"The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease","volume":"51","author":"Gibb","year":"1988","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD004554.pub2-BIB0060|cit60","first-page":"985","article-title":"When should levodopa be started?","volume":"ii","author":"Quinn","year":"1984","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004554.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1212\/WNL.34.8.991","article-title":"Chronic low-dose levodopa therapy in Parkinson's disease","volume":"34","author":"Rajput","year":"1984","journal-title":"Neurology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD004554.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T08:07:14Z","timestamp":1757146034000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004554.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Movement Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2004,10,18]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004554.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10,18]]}}}